MedPage Today June 5, 2024
Joyce Frieden

— “Even with some variation, there’s still reasonably good protection”

An FDA advisory committee voted unanimously, 16-0, Wednesday to recommend that the COVID-19 vaccines for the 2024-2025 season target the JN.1 strain of the virus.

“From my review of the data, it appeared that the newer variants that are appearing — KP.2, KP.3, and maybe some others that are coming up — the potential for immunogenicity from a JN.1 vaccine to cover those variants seems to be pretty good,” said Archana Chatterjee, MD, PhD, of Rosalind Franklin University of Medicine and Science in Chicago. “Antigenically they are close, and from the experience we had with [the] XBB [strain], it appears even with some variation, there’s still reasonably good protection. So...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article